Business
Medicure Announces FDA Approval Received for Prexxartan®
Medicure Announces FDA Approval Received for Prexxartan® Canada NewsWire WI...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure Announces FDA Approval Received for Prexxartan®\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, Dec. 19, 2017\n\n\n\nWINNIPEG, Dec. 19, 2017 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, today announced that Carmel Biosciences, Inc. (\"Carmel\") has received final approval of its New Drug Application from the US Food and Drug Administration (\"FDA\") for Prexxartan® (valsartan) oral solution. The FDA approval of Prexxartan® makes it the first and only approved oral liquid dosage form of the angiotensin II receptor blocker (\"ARB\") valsartan in the United States.\n\nPreviously, on October 31, 2017, Medicure announced that, through its subsidiary, Medicure International Inc., it had acquired a license to sell and market Prexxartan® in the United States and its territories from Carmel for a seven year term, with potential extensions to the term available. The Company intends to launch the product using its existing commercial sales force and infrastructure with a target commercial launch date during the first half of 2018. \n\nAdditionally, the Company announced that its Board of Directors has approved the grant of an aggregate of 576,000 stock options to certain directors, officers, employees, management company employees and consultants of the Company pursuant to its stock option plan. These options, which are subject to the approval of the TSX Venture Exchange, are set to expire on the fifth anniversary of the date of grant and will be issued at an exercise price of $7.20 per share.  \n\nAbout Medicure Inc.Medicure is a pharmaceutical company focused on the development and commercialization of therapeutics for the U.S. cardiovascular market. The primary focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) in the United States, where it is sold through the Company's U.S. subsidiary, Medicure Pharma, Inc. For more information on Medicure please visit www.medicure.com. \n\nNeither...